With annual revenue of $58.8bn and an R&D expenditure of $9.9bn, this Swiss pharmaceutical company ranks one in drug sales.
Its research work conducted through the "Novartis Institutes for BioMedical Research (NIBR)" focus on several arenas including diseases in the developing world. It lost the rights to patent its cancer drug ‘ Gleevec’ in India.
Novartis is focused in three broad areas: Pharmaceuticals, Alcon and Sandoz. Alcon is the Eye Care division and Sandoz is the generic division which is retail focused.
Novartis employees approximately 136000 employees worldwide. Novartis came into existence in 1996 with merger of Ciba-Geigy and Sandoz. Novartis also has opened a R&D Centre in Hyderabad India for R&D and other administrative taks.